Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. ESPR Peers
See (ESPR) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ESPR | $0.91 | +5.19% | 180.10M | -1.07 | -$0.85 | N/A |
| ZTS | $163.65 | -0.18% | 72.86B | 29.33 | $5.58 | +1.14% |
| HLN | $11.02 | +1.29% | 49.70B | 26.24 | $0.42 | +1.53% |
| TAK | $14.26 | +0.18% | 44.86B | 61.98 | $0.23 | +4.15% |
| TEVA | $16.79 | -1.35% | 19.24B | -14.60 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14.05B | -180.64 | -$0.73 | N/A |
| NBIX | $122.96 | +0.11% | 12.17B | 41.68 | $2.95 | N/A |
| RDY | $14.50 | +0.28% | 12.08B | 18.35 | $0.79 | +0.66% |
| CTLT | $63.48 | N/A | 11.52B | -27.84 | -$2.28 | N/A |
| VTRS | $8.88 | +1.37% | 10.42B | -2.79 | -$3.18 | +5.41% |
Stock Comparison
ESPR vs ZTS Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ZTS has a market cap of 72.86B. Regarding current trading prices, ESPR is priced at $0.91, while ZTS trades at $163.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ZTS's P/E ratio is 29.33. In terms of profitability, ESPR's ROE is +0.40%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ESPR is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs HLN Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, HLN has a market cap of 49.70B. Regarding current trading prices, ESPR is priced at $0.91, while HLN trades at $11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas HLN's P/E ratio is 26.24. In terms of profitability, ESPR's ROE is +0.40%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ESPR is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs TAK Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TAK has a market cap of 44.86B. Regarding current trading prices, ESPR is priced at $0.91, while TAK trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TAK's P/E ratio is 61.98. In terms of profitability, ESPR's ROE is +0.40%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ESPR is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs TEVA Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TEVA has a market cap of 19.24B. Regarding current trading prices, ESPR is priced at $0.91, while TEVA trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TEVA's P/E ratio is -14.60. In terms of profitability, ESPR's ROE is +0.40%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ESPR is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ITCI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ITCI has a market cap of 14.05B. Regarding current trading prices, ESPR is priced at $0.91, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ESPR's ROE is +0.40%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ESPR is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs NBIX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, NBIX has a market cap of 12.17B. Regarding current trading prices, ESPR is priced at $0.91, while NBIX trades at $122.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas NBIX's P/E ratio is 41.68. In terms of profitability, ESPR's ROE is +0.40%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ESPR is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs RDY Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, RDY has a market cap of 12.08B. Regarding current trading prices, ESPR is priced at $0.91, while RDY trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas RDY's P/E ratio is 18.35. In terms of profitability, ESPR's ROE is +0.40%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ESPR is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs CTLT Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CTLT has a market cap of 11.52B. Regarding current trading prices, ESPR is priced at $0.91, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ESPR's ROE is +0.40%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ESPR is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs VTRS Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, VTRS has a market cap of 10.42B. Regarding current trading prices, ESPR is priced at $0.91, while VTRS trades at $8.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas VTRS's P/E ratio is -2.79. In terms of profitability, ESPR's ROE is +0.40%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ESPR is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ELAN Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ELAN has a market cap of 6.50B. Regarding current trading prices, ESPR is priced at $0.91, while ELAN trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ELAN's P/E ratio is 17.44. In terms of profitability, ESPR's ROE is +0.40%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ESPR is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs RGC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, RGC has a market cap of 5.85B. Regarding current trading prices, ESPR is priced at $0.91, while RGC trades at $449.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas RGC's P/E ratio is -1404.84. In terms of profitability, ESPR's ROE is +0.40%, compared to RGC's ROE of -0.25%. Regarding short-term risk, ESPR is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs LNTH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, LNTH has a market cap of 5.32B. Regarding current trading prices, ESPR is priced at $0.91, while LNTH trades at $76.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas LNTH's P/E ratio is 21.89. In terms of profitability, ESPR's ROE is +0.40%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ESPR is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs PRGO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, PRGO has a market cap of 3.77B. Regarding current trading prices, ESPR is priced at $0.91, while PRGO trades at $27.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas PRGO's P/E ratio is -22.85. In terms of profitability, ESPR's ROE is +0.40%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ESPR is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs AMRX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, AMRX has a market cap of 3.45B. Regarding current trading prices, ESPR is priced at $0.91, while AMRX trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas AMRX's P/E ratio is -185.50. In terms of profitability, ESPR's ROE is +0.40%, compared to AMRX's ROE of -0.00%. Regarding short-term risk, ESPR is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ALVOW Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ALVOW has a market cap of 3.04B. Regarding current trading prices, ESPR is priced at $0.91, while ALVOW trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ESPR's ROE is +0.40%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ESPR is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ALVO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ALVO has a market cap of 2.95B. Regarding current trading prices, ESPR is priced at $0.91, while ALVO trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ALVO's P/E ratio is 26.43. In terms of profitability, ESPR's ROE is +0.40%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ESPR is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs HCM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, HCM has a market cap of 2.31B. Regarding current trading prices, ESPR is priced at $0.91, while HCM trades at $13.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas HCM's P/E ratio is 66.35. In terms of profitability, ESPR's ROE is +0.40%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ESPR is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs DCPH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, DCPH has a market cap of 2.21B. Regarding current trading prices, ESPR is priced at $0.91, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ESPR's ROE is +0.40%, compared to DCPH's ROE of -0.52%. Regarding short-term risk, ESPR is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs EMBCV Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, EMBCV has a market cap of 1.91B. Regarding current trading prices, ESPR is priced at $0.91, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ESPR's ROE is +0.40%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ESPR is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs SUPN Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SUPN has a market cap of 1.86B. Regarding current trading prices, ESPR is priced at $0.91, while SUPN trades at $33.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SUPN's P/E ratio is 29.91. In terms of profitability, ESPR's ROE is +0.40%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ESPR is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs BGM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, BGM has a market cap of 1.80B. Regarding current trading prices, ESPR is priced at $0.91, while BGM trades at $12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas BGM's P/E ratio is -61.75. In terms of profitability, ESPR's ROE is +0.40%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ESPR is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs BHC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, BHC has a market cap of 1.73B. Regarding current trading prices, ESPR is priced at $0.91, while BHC trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas BHC's P/E ratio is -39.00. In terms of profitability, ESPR's ROE is +0.40%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ESPR is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs TARO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TARO has a market cap of 1.62B. Regarding current trading prices, ESPR is priced at $0.91, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TARO's P/E ratio is 30.05. In terms of profitability, ESPR's ROE is +0.40%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ESPR is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs EVO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, EVO has a market cap of 1.45B. Regarding current trading prices, ESPR is priced at $0.91, while EVO trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas EVO's P/E ratio is -6.26. In terms of profitability, ESPR's ROE is +0.40%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ESPR is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs INDV Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, INDV has a market cap of 1.43B. Regarding current trading prices, ESPR is priced at $0.91, while INDV trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas INDV's P/E ratio is -228.80. In terms of profitability, ESPR's ROE is +0.40%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ESPR is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ANIP Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ANIP has a market cap of 1.31B. Regarding current trading prices, ESPR is priced at $0.91, while ANIP trades at $60.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ANIP's P/E ratio is -51.39. In terms of profitability, ESPR's ROE is +0.40%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ESPR is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs DVAX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, DVAX has a market cap of 1.25B. Regarding current trading prices, ESPR is priced at $0.91, while DVAX trades at $10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas DVAX's P/E ratio is -20.84. In terms of profitability, ESPR's ROE is +0.40%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ESPR is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs PCRX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, PCRX has a market cap of 1.24B. Regarding current trading prices, ESPR is priced at $0.91, while PCRX trades at $26.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas PCRX's P/E ratio is -11.94. In terms of profitability, ESPR's ROE is +0.40%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ESPR is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs AMPH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, AMPH has a market cap of 1.18B. Regarding current trading prices, ESPR is priced at $0.91, while AMPH trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas AMPH's P/E ratio is 9.08. In terms of profitability, ESPR's ROE is +0.40%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ESPR is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs HROW Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, HROW has a market cap of 1.03B. Regarding current trading prices, ESPR is priced at $0.91, while HROW trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas HROW's P/E ratio is -46.02. In terms of profitability, ESPR's ROE is +0.40%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ESPR is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs PAHC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, PAHC has a market cap of 976.45M. Regarding current trading prices, ESPR is priced at $0.91, while PAHC trades at $24.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas PAHC's P/E ratio is 30.88. In terms of profitability, ESPR's ROE is +0.40%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ESPR is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs COLL Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, COLL has a market cap of 962.98M. Regarding current trading prices, ESPR is priced at $0.91, while COLL trades at $29.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas COLL's P/E ratio is 24.56. In terms of profitability, ESPR's ROE is +0.40%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ESPR is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs PETQ Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, PETQ has a market cap of 919.17M. Regarding current trading prices, ESPR is priced at $0.91, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ESPR's ROE is +0.40%, compared to PETQ's ROE of +0.06%. Regarding short-term risk, ESPR is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs AVDL Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, AVDL has a market cap of 906.44M. Regarding current trading prices, ESPR is priced at $0.91, while AVDL trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas AVDL's P/E ratio is -36.04. In terms of profitability, ESPR's ROE is +0.40%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ESPR is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs CRON Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CRON has a market cap of 805.53M. Regarding current trading prices, ESPR is priced at $0.91, while CRON trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CRON's P/E ratio is 14.93. In terms of profitability, ESPR's ROE is +0.40%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ESPR is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs EMBC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, EMBC has a market cap of 718.26M. Regarding current trading prices, ESPR is priced at $0.91, while EMBC trades at $12.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas EMBC's P/E ratio is 13.81. In terms of profitability, ESPR's ROE is +0.40%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ESPR is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs EOLS Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, EOLS has a market cap of 642.18M. Regarding current trading prices, ESPR is priced at $0.91, while EOLS trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas EOLS's P/E ratio is -11.19. In terms of profitability, ESPR's ROE is +0.40%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ESPR is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs BDSI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, BDSI has a market cap of 577.05M. Regarding current trading prices, ESPR is priced at $0.91, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ESPR's ROE is +0.40%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ESPR is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs TLRY Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TLRY has a market cap of 464.46M. Regarding current trading prices, ESPR is priced at $0.91, while TLRY trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TLRY's P/E ratio is -0.41. In terms of profitability, ESPR's ROE is +0.40%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ESPR is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ORGO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ORGO has a market cap of 413.54M. Regarding current trading prices, ESPR is priced at $0.91, while ORGO trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ORGO's P/E ratio is -20.37. In terms of profitability, ESPR's ROE is +0.40%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ESPR is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs KMDA Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, KMDA has a market cap of 395.06M. Regarding current trading prices, ESPR is priced at $0.91, while KMDA trades at $6.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas KMDA's P/E ratio is 24.54. In terms of profitability, ESPR's ROE is +0.40%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ESPR is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs SIGA Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SIGA has a market cap of 390.58M. Regarding current trading prices, ESPR is priced at $0.91, while SIGA trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SIGA's P/E ratio is 4.56. In terms of profitability, ESPR's ROE is +0.40%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ESPR is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs EBS Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, EBS has a market cap of 376.69M. Regarding current trading prices, ESPR is priced at $0.91, while EBS trades at $6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas EBS's P/E ratio is -2.69. In terms of profitability, ESPR's ROE is +0.40%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ESPR is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ZYBT Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ZYBT has a market cap of 367.28M. Regarding current trading prices, ESPR is priced at $0.91, while ZYBT trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ZYBT's P/E ratio is 129.17. In terms of profitability, ESPR's ROE is +0.40%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ESPR is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs TKNO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TKNO has a market cap of 359.12M. Regarding current trading prices, ESPR is priced at $0.91, while TKNO trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TKNO's P/E ratio is -14.61. In terms of profitability, ESPR's ROE is +0.40%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ESPR is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs SNDL Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SNDL has a market cap of 342.21M. Regarding current trading prices, ESPR is priced at $0.91, while SNDL trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SNDL's P/E ratio is -4.59. In terms of profitability, ESPR's ROE is +0.40%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ESPR is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs CGC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CGC has a market cap of 318.74M. Regarding current trading prices, ESPR is priced at $0.91, while CGC trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CGC's P/E ratio is -0.49. In terms of profitability, ESPR's ROE is +0.40%, compared to CGC's ROE of -0.88%. Regarding short-term risk, ESPR is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs ALIM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ALIM has a market cap of 301.29M. Regarding current trading prices, ESPR is priced at $0.91, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ESPR's ROE is +0.40%, compared to ALIM's ROE of -0.34%. Regarding short-term risk, ESPR is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ACB Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ACB has a market cap of 293.08M. Regarding current trading prices, ESPR is priced at $0.91, while ACB trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ACB's P/E ratio is 28.11. In terms of profitability, ESPR's ROE is +0.40%, compared to ACB's ROE of -0.06%. Regarding short-term risk, ESPR is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs LNDC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, LNDC has a market cap of 263.63M. Regarding current trading prices, ESPR is priced at $0.91, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ESPR's ROE is +0.40%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ESPR is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs LFCR Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, LFCR has a market cap of 245.48M. Regarding current trading prices, ESPR is priced at $0.91, while LFCR trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas LFCR's P/E ratio is -4.51. In terms of profitability, ESPR's ROE is +0.40%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ESPR is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs AQST Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, AQST has a market cap of 237.39M. Regarding current trading prices, ESPR is priced at $0.91, while AQST trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas AQST's P/E ratio is -4.12. In terms of profitability, ESPR's ROE is +0.40%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ESPR is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs TYHT Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TYHT has a market cap of 229.17M. Regarding current trading prices, ESPR is priced at $0.91, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ESPR's ROE is +0.40%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ESPR is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs OGI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, OGI has a market cap of 180.68M. Regarding current trading prices, ESPR is priced at $0.91, while OGI trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas OGI's P/E ratio is 10.38. In terms of profitability, ESPR's ROE is +0.40%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ESPR is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs REPH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, REPH has a market cap of 177.42M. Regarding current trading prices, ESPR is priced at $0.91, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas REPH's P/E ratio is -8.04. In terms of profitability, ESPR's ROE is +0.40%, compared to REPH's ROE of -0.15%. Regarding short-term risk, ESPR is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs DERM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, DERM has a market cap of 160.27M. Regarding current trading prices, ESPR is priced at $0.91, while DERM trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas DERM's P/E ratio is -18.59. In terms of profitability, ESPR's ROE is +0.40%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ESPR is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs BIOA Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, BIOA has a market cap of 147.34M. Regarding current trading prices, ESPR is priced at $0.91, while BIOA trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas BIOA's P/E ratio is -2.08. In terms of profitability, ESPR's ROE is +0.40%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ESPR is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs THTX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, THTX has a market cap of 120.01M. Regarding current trading prices, ESPR is priced at $0.91, while THTX trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas THTX's P/E ratio is -37.29. In terms of profitability, ESPR's ROE is +0.40%, compared to THTX's ROE of +0.16%. Regarding short-term risk, ESPR is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs SCTL Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SCTL has a market cap of 116.13M. Regarding current trading prices, ESPR is priced at $0.91, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ESPR's ROE is +0.40%, compared to SCTL's ROE of -0.15%. Regarding short-term risk, ESPR is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs PROC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, PROC has a market cap of 113.95M. Regarding current trading prices, ESPR is priced at $0.91, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas PROC's P/E ratio is 1.53. In terms of profitability, ESPR's ROE is +0.40%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ESPR is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs IRWD Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, IRWD has a market cap of 105.57M. Regarding current trading prices, ESPR is priced at $0.91, while IRWD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas IRWD's P/E ratio is -3.43. In terms of profitability, ESPR's ROE is +0.40%, compared to IRWD's ROE of +0.01%. Regarding short-term risk, ESPR is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs OPTN Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, OPTN has a market cap of 97.22M. Regarding current trading prices, ESPR is priced at $0.91, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ESPR's ROE is +0.40%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ESPR is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ZOM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ZOM has a market cap of 95.35M. Regarding current trading prices, ESPR is priced at $0.91, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ESPR's ROE is +0.40%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ESPR is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs CRDL Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CRDL has a market cap of 92.54M. Regarding current trading prices, ESPR is priced at $0.91, while CRDL trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CRDL's P/E ratio is -3.29. In terms of profitability, ESPR's ROE is +0.40%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, ESPR is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs GRVI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, GRVI has a market cap of 88.91M. Regarding current trading prices, ESPR is priced at $0.91, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ESPR's ROE is +0.40%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, ESPR is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs INCR Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, INCR has a market cap of 75.46M. Regarding current trading prices, ESPR is priced at $0.91, while INCR trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas INCR's P/E ratio is -4.00. In terms of profitability, ESPR's ROE is +0.40%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ESPR is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs CPIX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CPIX has a market cap of 75.25M. Regarding current trading prices, ESPR is priced at $0.91, while CPIX trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CPIX's P/E ratio is -20.96. In terms of profitability, ESPR's ROE is +0.40%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ESPR is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs ZYNE Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ZYNE has a market cap of 70.12M. Regarding current trading prices, ESPR is priced at $0.91, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ESPR's ROE is +0.40%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ESPR is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs SSIC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SSIC has a market cap of 66.72M. Regarding current trading prices, ESPR is priced at $0.91, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ESPR's ROE is +0.40%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, ESPR is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ASRT Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ASRT has a market cap of 65.72M. Regarding current trading prices, ESPR is priced at $0.91, while ASRT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ASRT's P/E ratio is -2.14. In terms of profitability, ESPR's ROE is +0.40%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ESPR is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs VLNS Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, VLNS has a market cap of 61.46M. Regarding current trading prices, ESPR is priced at $0.91, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ESPR's ROE is +0.40%, compared to VLNS's ROE of N/A. Regarding short-term risk, ESPR is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs JUPW Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, JUPW has a market cap of 49.33M. Regarding current trading prices, ESPR is priced at $0.91, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ESPR's ROE is +0.40%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ESPR is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs QLI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, QLI has a market cap of 38.68M. Regarding current trading prices, ESPR is priced at $0.91, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas QLI's P/E ratio is -4.92. In terms of profitability, ESPR's ROE is +0.40%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ESPR is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs RMTI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, RMTI has a market cap of 36.74M. Regarding current trading prices, ESPR is priced at $0.91, while RMTI trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas RMTI's P/E ratio is -107.50. In terms of profitability, ESPR's ROE is +0.40%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ESPR is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs HEXO Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, HEXO has a market cap of 31.24M. Regarding current trading prices, ESPR is priced at $0.91, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ESPR's ROE is +0.40%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ESPR is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs SCYX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SCYX has a market cap of 31.19M. Regarding current trading prices, ESPR is priced at $0.91, while SCYX trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SCYX's P/E ratio is -1.43. In terms of profitability, ESPR's ROE is +0.40%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ESPR is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs QNTM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, QNTM has a market cap of 26.19M. Regarding current trading prices, ESPR is priced at $0.91, while QNTM trades at $11.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas QNTM's P/E ratio is -0.86. In terms of profitability, ESPR's ROE is +0.40%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ESPR is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs KALA Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, KALA has a market cap of 25.49M. Regarding current trading prices, ESPR is priced at $0.91, while KALA trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas KALA's P/E ratio is -0.39. In terms of profitability, ESPR's ROE is +0.40%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ESPR is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs EGRX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, EGRX has a market cap of 25.14M. Regarding current trading prices, ESPR is priced at $0.91, while EGRX trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas EGRX's P/E ratio is 2.28. In terms of profitability, ESPR's ROE is +0.40%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ESPR is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs SXTC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SXTC has a market cap of 25.00M. Regarding current trading prices, ESPR is priced at $0.91, while SXTC trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SXTC's P/E ratio is 0.01. In terms of profitability, ESPR's ROE is +0.40%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ESPR is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs CYTH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CYTH has a market cap of 23.59M. Regarding current trading prices, ESPR is priced at $0.91, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ESPR's ROE is +0.40%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ESPR is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs DRRX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, DRRX has a market cap of 18.94M. Regarding current trading prices, ESPR is priced at $0.91, while DRRX trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas DRRX's P/E ratio is -1.27. In terms of profitability, ESPR's ROE is +0.40%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ESPR is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs TXMD Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TXMD has a market cap of 17.25M. Regarding current trading prices, ESPR is priced at $0.91, while TXMD trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TXMD's P/E ratio is -7.84. In terms of profitability, ESPR's ROE is +0.40%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ESPR is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs GELS Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, GELS has a market cap of 16.14M. Regarding current trading prices, ESPR is priced at $0.91, while GELS trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas GELS's P/E ratio is -7.12. In terms of profitability, ESPR's ROE is +0.40%, compared to GELS's ROE of -0.21%. Regarding short-term risk, ESPR is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs FLGC Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, FLGC has a market cap of 14.72M. Regarding current trading prices, ESPR is priced at $0.91, while FLGC trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas FLGC's P/E ratio is -0.50. In terms of profitability, ESPR's ROE is +0.40%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ESPR is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs ACRX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ACRX has a market cap of 14.58M. Regarding current trading prices, ESPR is priced at $0.91, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ESPR's ROE is +0.40%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ESPR is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs SISI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, SISI has a market cap of 14.41M. Regarding current trading prices, ESPR is priced at $0.91, while SISI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas SISI's P/E ratio is -0.01. In terms of profitability, ESPR's ROE is +0.40%, compared to SISI's ROE of -1.41%. Regarding short-term risk, ESPR is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs PRPH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, PRPH has a market cap of 13.72M. Regarding current trading prices, ESPR is priced at $0.91, while PRPH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas PRPH's P/E ratio is -0.14. In terms of profitability, ESPR's ROE is +0.40%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, ESPR is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs COSM Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, COSM has a market cap of 12.85M. Regarding current trading prices, ESPR is priced at $0.91, while COSM trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas COSM's P/E ratio is -0.38. In terms of profitability, ESPR's ROE is +0.40%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ESPR is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs AYTU Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, AYTU has a market cap of 12.53M. Regarding current trading prices, ESPR is priced at $0.91, while AYTU trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas AYTU's P/E ratio is -1.36. In terms of profitability, ESPR's ROE is +0.40%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ESPR is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs TLPH Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, TLPH has a market cap of 10.64M. Regarding current trading prices, ESPR is priced at $0.91, while TLPH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas TLPH's P/E ratio is -1.04. In terms of profitability, ESPR's ROE is +0.40%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ESPR is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs AGRX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, AGRX has a market cap of 10.43M. Regarding current trading prices, ESPR is priced at $0.91, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ESPR's ROE is +0.40%, compared to AGRX's ROE of +1.04%. Regarding short-term risk, ESPR is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs YCBD Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, YCBD has a market cap of 8.58M. Regarding current trading prices, ESPR is priced at $0.91, while YCBD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas YCBD's P/E ratio is -0.09. In terms of profitability, ESPR's ROE is +0.40%, compared to YCBD's ROE of -8.81%. Regarding short-term risk, ESPR is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs NLTX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, NLTX has a market cap of 8.20M. Regarding current trading prices, ESPR is priced at $0.91, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ESPR's ROE is +0.40%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, ESPR is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs CPHI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, CPHI has a market cap of 7.83M. Regarding current trading prices, ESPR is priced at $0.91, while CPHI trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas CPHI's P/E ratio is -1.08. In terms of profitability, ESPR's ROE is +0.40%, compared to CPHI's ROE of -0.45%. Regarding short-term risk, ESPR is more volatile compared to CPHI. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs LCI Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, LCI has a market cap of 7.38M. Regarding current trading prices, ESPR is priced at $0.91, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas LCI's P/E ratio is -0.04. In terms of profitability, ESPR's ROE is +0.40%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ESPR is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.
ESPR vs BGXX Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, BGXX has a market cap of 7.26M. Regarding current trading prices, ESPR is priced at $0.91, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ESPR's ROE is +0.40%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, ESPR is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs ADMP Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, ADMP has a market cap of 7.25M. Regarding current trading prices, ESPR is priced at $0.91, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ESPR's ROE is +0.40%, compared to ADMP's ROE of +0.00%. Regarding short-term risk, ESPR is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for ESPR.
ESPR vs IXHL Comparison
ESPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ESPR stands at 180.10M. In comparison, IXHL has a market cap of 7.06M. Regarding current trading prices, ESPR is priced at $0.91, while IXHL trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ESPR currently has a P/E ratio of -1.07, whereas IXHL's P/E ratio is -0.17. In terms of profitability, ESPR's ROE is +0.40%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, ESPR is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ESPR.